{
  "title": "Outlook for Gilead’s COVID-19 Treatment",
  "itunes:title": "Outlook for Gilead’s COVID-19 Treatment",
  "description": "<p>Bloomberg News Senate Reporter Steve Dennis discusses Democrats blocking Senate Majority Leader Mitch McConnell’s push to boost small business aid. Dr. Chris Beyrer, Professor of Epidemiology at the Johns Hopkins Bloomberg School of Public Health, provides a coronavirus update and breaks down how the outbreak is impacting the prison population. Bloomberg Businessweek Editor Joel Weber and Bloomberg News P&I Reporter Drake Bennett walk through Zoom going from a conferencing app to becoming the pandemic’s social network. We get caught up on Businessweek Economics with Bloomberg News Global Economics and Policy Editor Kathleen Hays and Bloomberg Economics Chief U.S. Economist Carl Riccadonna. Brian Skorney, Biotech and Pharma Analyst at Baird, shares his outlook for Gilead's Remdesivir drug as treatment for COVID-19. And we Drive to the Close with Wayne Wicker, Chief Investment Officer at Vantagepoint Investment Advisers.</p><p>Hosts: Carol Massar and Jason Kelly. Producer: Doni Holloway.</p><p><br></p><p>See <a href=\"https://omnystudio.com/listener\">omnystudio.com/listener</a> for privacy information.</p>",
  "content:encoded": "<p>Bloomberg News Senate Reporter Steve Dennis discusses Democrats blocking Senate Majority Leader Mitch McConnell’s push to boost small business aid. Dr. Chris Beyrer, Professor of Epidemiology at the Johns Hopkins Bloomberg School of Public Health, provides a coronavirus update and breaks down how the outbreak is impacting the prison population. Bloomberg Businessweek Editor Joel Weber and Bloomberg News P&I Reporter Drake Bennett walk through Zoom going from a conferencing app to becoming the pandemic’s social network. We get caught up on Businessweek Economics with Bloomberg News Global Economics and Policy Editor Kathleen Hays and Bloomberg Economics Chief U.S. Economist Carl Riccadonna. Brian Skorney, Biotech and Pharma Analyst at Baird, shares his outlook for Gilead's Remdesivir drug as treatment for COVID-19. And we Drive to the Close with Wayne Wicker, Chief Investment Officer at Vantagepoint Investment Advisers.</p><p>Hosts: Carol Massar and Jason Kelly. Producer: Doni Holloway.</p><p><br></p><p>See <a href=\"https://omnystudio.com/listener\">omnystudio.com/listener</a> for privacy information.</p>",
  "itunes:episodeType": "full",
  "itunes:author": "Bloomberg",
  "itunes:image": "",
  "media:content": [
    {
      "media:player": ""
    },
    ""
  ],
  "guid": "bbf26228-7abf-11ea-9d3c-ef62f6ceac56",
  "omny:clipId": "4f310746-fd0f-4efa-98e2-ae2b007b3156",
  "pubDate": "Fri, 10 Apr 2020 00:23:44 +0000",
  "itunes:duration": 2509,
  "enclosure": "",
  "link": "https://omny.fm/shows/bloomberg-businessweek/outlook-for-gilead-s-covid-19-treatment"
}